Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study
Pacing and Clinical Electrophysiology · 2026
DOI: 10.1111/pace.70301 ↗At a glance
Multizentrische Studie in Pacing and Clinical Electrophysiology, 2026. Written by Akinori Sairaku and 5 co-authors. Institution: Department of Cardiology, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan. Major MEDLINE topics: Anti-Arrhythmia Agents, Atrial Flutter, Magnesium Sulfate, Pyrimidinones. 13 references.
Abstract (original language)
Background
Pharmacologic cardioversion of atrial flutter (AFL) remains challenging, particularly in older or frail patients who are not candidates for catheter ablation. Nifekalant is effective for AFL but is limited by QT prolongation and the risk of torsades de pointes (TdP). Magnesium sulfate may mitigate this risk.
Methods
In this multicenter, investigator‐initiated pilot study, 86 patients with symptomatic persistent AFL received intravenous magnesium sulfate followed by nifekalant. The primary outcome was AFL termination within 60 min. Time to termination and safety outcomes, including TdP, were assessed. Multivariable logistic regression analyses were performed to identify factors associated with AFL termination.
Results
AFL terminated in 42 patients (48.8%). Among patients with successful cardioversion, 80% achieved termination within 20 min. Larger left atrial diameter was associated with a lower likelihood of AFL termination. Adverse events occurred in 2 patients (2.3%), including sinus pauses requiring pacemaker implantation and transient hypotension requiring vasopressor support. No cases of TdP were observed.
Conclusions
These findings suggest that the nifekalant–magnesium cocktail may be a feasible and potentially safe option for chemical cardioversion of AFL, warranting further investigation in larger studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiology, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.
- Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
- Department of Cardiology, Onomichi General Hospital, Onomichi, Japan.
- Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
- Department of Cardiology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
ORCID profiles: Akinori Sairaku, Shunsuke Tomomori
Cite
APA
Sairaku, A., Amioka, M., Watanabe, Y., Tomomori, S., Fukuda, Y., & Nakano, Y. (2026). Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.70301
Vancouver
Sairaku A, Amioka M, Watanabe Y, Tomomori S, Fukuda Y, Nakano Y. Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study. Pacing and Clinical Electrophysiology. 2026. doi:10.1111/pace.70301
BibTeX
@article{Sairaku2026,
author = {Sairaku, Akinori and Amioka, Michitaka and Watanabe, Yoshikazu and Tomomori, Shunsuke and Fukuda, Yukihiro and Nakano, Yukiko},
title = {Nifekalant–Magnesium Cocktail for Chemical Cardioversion of Atrial Flutter: A Multicenter Pilot Study},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
doi = {10.1111/pace.70301}
}
EUVIMED